Who Paid My Doc
Epanova
Drug Cardiovascular And Metabolism
NDC 0310-2222-60
General payments
$254,950
Research payments
$15,357,957
Through program year 2025, $254,950 in general payments and $15,357,957 in research payments were reported against Epanova (Cardiovascular And Metabolism).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
11 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $617 | 21 |
| 2024 | General | $817 | 29 |
| 2023 | General | $473 | 22 |
| 2022 | General | $240 | 14 |
| 2022 | Research | $33,140 | 2 |
| 2021 | General | $29,951 | 47 |
| 2021 | Research | $247,002 | 64 |
| 2020 | General | $126,937 | 59 |
| 2020 | Research | $8,598,522 | 561 |
| 2019 | General | $95,915 | 79 |
| 2019 | Research | $6,479,293 | 996 |
Breakdown
The top 5 of 18 recipients; each share is of general payments naming this product in 2025.
The top 5 of 8 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 6 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
271 general · 1,623 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.